Matches in Nanopublications for { ?s ?p ?o <http://www.tkuhn.ch/bel2nanopub/RAodTYYpdZLTTlPML2kGJSaZbSl6sgC784o7OA3a4v2dw#provenance>. }
Showing items 1 to 11 of
11
with 100 items per page.
- _5 label "Selventa" provenance.
- large_corpus.bel title "BEL Framework Large Corpus Document" provenance.
- large_corpus.bel description "Approximately 61,000 statements." provenance.
- large_corpus.bel version "20131211" provenance.
- large_corpus.bel authoredBy _5 provenance.
- assertion wasDerivedFrom large_corpus.bel provenance.
- assertion wasDerivedFrom _4 provenance.
- assertion hadPrimarySource 15578112 provenance.
- _4 wasQuotedFrom 15578112 provenance.
- _4 value "Rosiglitazone has marked anti-inflammatory effects on macrophages [31]. This led us to examine the effect of aspirin, an anti-inflammatory compound that targets IkB kinase and has insulin-sensitizing effects [32]. Remarkably, aspirin dramatically decreased endotoxin-induced resistin expression in a dose-dependent manner (Figure 4C). Both aspirin (via IkB kinase) and rosiglitazone (via PPARg) inhibit NF-kB [31,32], which is activated by LPS. Indeed, treatment of the macrophages with the proteasome inhibitor MG132, which prevents NF-kB activation [33], abrogated endotoxin-induced activation of resistin expression (data not shown). Moreover, treatment of the macrophages with SN50, a cell-permeable peptide that specifically prevents activation of NF-kB by inhibiting its nuclear translocation [34], nearly abolished endotoxin-induced activation of resistin expression (Figure 4D). Thus, activation of NF-kB is required for LPS induction of resistin in human macrophages." provenance.
- large_corpus.bel rights "Copyright (c) 2011-2012, Selventa. All rights reserved." provenance.